Recruitment

Recruitment Status
Completed
Estimated Enrollment
100

Inclusion Criteria

Subject has mild to moderate primary open glaucoma where the intraocular pressure is not adequately controlled on maximum tolerated medical therapy and has intraocular pressure greater than or equal to 18mmHg and less than or equal to 35mmHg while on glaucoma medications and/or where glaucoma progression warrants surgery.
Diffuse thinning, focal narrowing, or notching of the optic disc rim, especially at the inferior or superior poles.
Localized abnormalities of the peripapillary retinal nerve fiber layer, especially at the inferior or superior poles.
...
Subject has mild to moderate primary open glaucoma where the intraocular pressure is not adequately controlled on maximum tolerated medical therapy and has intraocular pressure greater than or equal to 18mmHg and less than or equal to 35mmHg while on glaucoma medications and/or where glaucoma progression warrants surgery.
Diffuse thinning, focal narrowing, or notching of the optic disc rim, especially at the inferior or superior poles.
Localized abnormalities of the peripapillary retinal nerve fiber layer, especially at the inferior or superior poles.
Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue.
Disc rim or peripapillary retinal nerve fiber layer hemorrhages.

Exclusion Criteria

Prior laser peripheral iridotomy.
Intraocular silicone oil.
Clinically significant sequelae from trauma (e.g., chemical burns, blunt trauma, etc.)
...
Prior laser peripheral iridotomy.
Intraocular silicone oil.
Clinically significant sequelae from trauma (e.g., chemical burns, blunt trauma, etc.)
Uveitis
Epithelial or fibrous downgrowth.
Conditions associated with elevated episcleral venous pressure such as active thyroid orbitopathy, cavernous sinus fistula, Sturge-Weber syndrome, orbital tumors, orbital congestive disease.
Diagnosed degenerative visual disorders not associated with existing glaucoma condition (e.g., advanced dry or wet macular degeneration or other retinal disorders, central retinal artery or vein occlusion) or choroidopathy (e.g., choroidal detachment, effusion, choroiditis, or neovascularization).
Active scleritis
Disorders that pose a fall risk, as well as compromise ability to take a visual field exam and take glaucoma medications (e.g., Parkinson's disease),
Severe myopia
Any condition that prevents the investigational device implantation or trabeculectomy in the superior region of the study eye (e.g., peripheral anterior synechiae, scleral staphyloma or conjunctival scarring).
Prior argon laser, selective laser, or micropulse trabeculoplasty within 90 days of enrollment.
Use of oral hypotensive glaucoma medications for treatment of the fellow eye.
known corticosteroid responders whose pressure increases would not allow them to withstand the postop corticosteroid regimen.
Endophthalmitis
Angle closure glaucoma or narrow anatomical chamber angle as identified by gonioscopy and classified as Shaffer Grade 0 or 1.
Bacteremia or septicemia
immunodeficiency concerns.
Previous cyclodestructive procedure.
Severe dry eye syndrome
Previous incisional ophthalmic surgery, excluding uncomplicated clear corneal phacoemulsification (cataract) surgery at least 6 months prior to enrollment.
Previous incisional ophthalmic surgery, excluding uncomplicated clear corneal phacoemulsification (cataract) surgery at least 6 months prior to enrollment.
Chronic ocular inflammatory disease.
Orbital cellulitis
Use of oral hypotensive glaucoma medications for treatment of the fellow eye.
Ocular steroid use in the planned study eye or systemic steroid use anytime within three months of the procedure. (This would not include the use of inhaled or dermatologic steroids.)
Bacterial corneal ulcers
Inability to obtain accurate IOP measurement throughout the study. For example: a history of corneal surgery, corneal opacities or disease/pathology (Active corneal infection or Fuchs dystrophy are examples.).
inability to reliably complete visual field testing over the course of the study,
Iridocorneal endothelial syndrome.
Severe anterior or posterior blepharitis.
Bacterial conjunctivitis
Central corneal thickness that is less than 450 microns or greater than 620 microns.
Fellow eye with poorer than 20/200 best-corrected visual acuity (BCVA)
Need for glaucoma surgery combined with other ocular procedures or anticipated need for additional ocular surgery during the investigational period.
inability to discontinue use of blood thinners within the surgeon's standard preoperative or postoperative instructions.
Prior laser peripheral iridotomy.
Known allergy or other contraindication to Mitomycin C (MMC) drug.
A requirement of general anesthesia for the procedure.
Secondary glaucoma such as post-trauma, pseudo-exfoliative, etc.
Fellow eye with poorer than 20/200 best-corrected visual acuity (BCVA)
Pseudo-exfoliative glaucoma
Previous cyclodestructive procedure.
Angle closure glaucoma or narrow anatomical chamber angle as identified by gonioscopy and classified as Shaffer Grade 0 or 1.
Unwilling to discontinue contact lens use after surgery.
Chemotherapy within six months of the screening visit.
Prior retinal laser procedure conducted for any purpose other than treatment of retinal tear or hole.
Severe anterior or posterior blepharitis.
Presence of an anterior chamber IOL (AC-IOL).
uncontrolled systemic disease (e.g. diabetes, hypertension) that could compromise their participation in the study.
Active iris neovascularization, active proliferative retinopathy or other ophthalmic disease that could confound study results.

Summary

Conditions
Primary Open Angle Glaucoma
Type
Interventional
Design
  • Allocation: N/A
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 85 years
Gender
Both males and females

Description

The purpose of this study is to collect additional safety and effectiveness data on the InnFocus MicroShunt (MIDI Arrow) in subjects suffering from primary open angle glaucoma who are inadequately controlled on maximum tolerated medical therapy with intraocular pressure ≥ 18 mm Hg and ≤ 35 mm Hg and...

The purpose of this study is to collect additional safety and effectiveness data on the InnFocus MicroShunt (MIDI Arrow) in subjects suffering from primary open angle glaucoma who are inadequately controlled on maximum tolerated medical therapy with intraocular pressure ≥ 18 mm Hg and ≤ 35 mm Hg and/or where glaucoma progression warrants surgery.

Inclusion Criteria

Subject has mild to moderate primary open glaucoma where the intraocular pressure is not adequately controlled on maximum tolerated medical therapy and has intraocular pressure greater than or equal to 18mmHg and less than or equal to 35mmHg while on glaucoma medications and/or where glaucoma progression warrants surgery.
Diffuse thinning, focal narrowing, or notching of the optic disc rim, especially at the inferior or superior poles.
Localized abnormalities of the peripapillary retinal nerve fiber layer, especially at the inferior or superior poles.
...
Subject has mild to moderate primary open glaucoma where the intraocular pressure is not adequately controlled on maximum tolerated medical therapy and has intraocular pressure greater than or equal to 18mmHg and less than or equal to 35mmHg while on glaucoma medications and/or where glaucoma progression warrants surgery.
Diffuse thinning, focal narrowing, or notching of the optic disc rim, especially at the inferior or superior poles.
Localized abnormalities of the peripapillary retinal nerve fiber layer, especially at the inferior or superior poles.
Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue.
Disc rim or peripapillary retinal nerve fiber layer hemorrhages.

Exclusion Criteria

Prior laser peripheral iridotomy.
Intraocular silicone oil.
Clinically significant sequelae from trauma (e.g., chemical burns, blunt trauma, etc.)
...
Prior laser peripheral iridotomy.
Intraocular silicone oil.
Clinically significant sequelae from trauma (e.g., chemical burns, blunt trauma, etc.)
Uveitis
Epithelial or fibrous downgrowth.
Conditions associated with elevated episcleral venous pressure such as active thyroid orbitopathy, cavernous sinus fistula, Sturge-Weber syndrome, orbital tumors, orbital congestive disease.
Diagnosed degenerative visual disorders not associated with existing glaucoma condition (e.g., advanced dry or wet macular degeneration or other retinal disorders, central retinal artery or vein occlusion) or choroidopathy (e.g., choroidal detachment, effusion, choroiditis, or neovascularization).
Active scleritis
Disorders that pose a fall risk, as well as compromise ability to take a visual field exam and take glaucoma medications (e.g., Parkinson's disease),
Severe myopia
Any condition that prevents the investigational device implantation or trabeculectomy in the superior region of the study eye (e.g., peripheral anterior synechiae, scleral staphyloma or conjunctival scarring).
Prior argon laser, selective laser, or micropulse trabeculoplasty within 90 days of enrollment.
Use of oral hypotensive glaucoma medications for treatment of the fellow eye.
known corticosteroid responders whose pressure increases would not allow them to withstand the postop corticosteroid regimen.
Endophthalmitis
Angle closure glaucoma or narrow anatomical chamber angle as identified by gonioscopy and classified as Shaffer Grade 0 or 1.
Bacteremia or septicemia
immunodeficiency concerns.
Previous cyclodestructive procedure.
Severe dry eye syndrome
Previous incisional ophthalmic surgery, excluding uncomplicated clear corneal phacoemulsification (cataract) surgery at least 6 months prior to enrollment.
Previous incisional ophthalmic surgery, excluding uncomplicated clear corneal phacoemulsification (cataract) surgery at least 6 months prior to enrollment.
Chronic ocular inflammatory disease.
Orbital cellulitis
Use of oral hypotensive glaucoma medications for treatment of the fellow eye.
Ocular steroid use in the planned study eye or systemic steroid use anytime within three months of the procedure. (This would not include the use of inhaled or dermatologic steroids.)
Bacterial corneal ulcers
Inability to obtain accurate IOP measurement throughout the study. For example: a history of corneal surgery, corneal opacities or disease/pathology (Active corneal infection or Fuchs dystrophy are examples.).
inability to reliably complete visual field testing over the course of the study,
Iridocorneal endothelial syndrome.
Severe anterior or posterior blepharitis.
Bacterial conjunctivitis
Central corneal thickness that is less than 450 microns or greater than 620 microns.
Fellow eye with poorer than 20/200 best-corrected visual acuity (BCVA)
Need for glaucoma surgery combined with other ocular procedures or anticipated need for additional ocular surgery during the investigational period.
inability to discontinue use of blood thinners within the surgeon's standard preoperative or postoperative instructions.
Prior laser peripheral iridotomy.
Known allergy or other contraindication to Mitomycin C (MMC) drug.
A requirement of general anesthesia for the procedure.
Secondary glaucoma such as post-trauma, pseudo-exfoliative, etc.
Fellow eye with poorer than 20/200 best-corrected visual acuity (BCVA)
Pseudo-exfoliative glaucoma
Previous cyclodestructive procedure.
Angle closure glaucoma or narrow anatomical chamber angle as identified by gonioscopy and classified as Shaffer Grade 0 or 1.
Unwilling to discontinue contact lens use after surgery.
Chemotherapy within six months of the screening visit.
Prior retinal laser procedure conducted for any purpose other than treatment of retinal tear or hole.
Severe anterior or posterior blepharitis.
Presence of an anterior chamber IOL (AC-IOL).
uncontrolled systemic disease (e.g. diabetes, hypertension) that could compromise their participation in the study.
Active iris neovascularization, active proliferative retinopathy or other ophthalmic disease that could confound study results.

Tracking Information

NCT #
NCT02177123
Collaborators
Not Provided
Investigators
Study Director: Guy Van de Weyer, Optometrist InnFocus Inc.
About Us
Innovation
Privacy
Terms
Copyright
Get Well Soon © Copyright 2024